AstraZeneca wins legal round in Teva Seroquel row

Tue Jul 1, 2008 10:39pm BST
 
Email | Print | | Single Page
[-] Text [+]

WASHINGTON (Reuters) - Teva Pharmaceutical Industries Ltd (TEVA.O) said on Tuesday that AstraZeneca Plc (AZN.L) won the latest court battle in their patent dispute over a generic version of AstraZeneca's blockbuster schizophrenia drug.

The U.S. District Court for the District of New Jersey granted summary judgment in AstraZeneca's favour in the case, according to Jerusalem-based Teva.

Teva, one of the world's biggest makers of generic drugs, said it would appeal the ruling.

AstraZeneca is fending off the threat of generic competition for Seroquel, which had $4 billion (2 billion pounds) in worldwide sales last year. It is known generically as quetiapine and is the company's second biggest seller.

(Reporting by Kim Dixon; editing by Jeffrey Benkoe)

 
Zhu Zhu pet
Can I have one for Christmas?

The hottest toy in the U.S. this Christmas is an interactive hamster. It does not come from one of the major toy brands or from a movie but a small, seven-year-old company from Missouri.  Full Coverage 

Photo

Market Update

  • UKUK
  • USUS
  • Europe
  • Asia
  • UK Most Actives

Most Popular Business News on Reuters UK

  • Articles
  • Videos